NEW YORK (GenomeWeb) – Helena Biosciences said today that it is collaborating with Ghent University to commercialize a glycoprotein-based blood test for chronic liver disease.

Called the Glyco Liver Profile, the test uses capillary electrophoresis to measure glycosylation of serum proteins, and uses this information to diagnose and monitor chronic liver diseases such as hepatic inflammation, fibrosis, and cirrhosis. The test also assesses cirrhosis patients' risk of developing liver cancer within the next five years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.